Stock Traders Purchase High Volume of Corbus Pharmaceuticals Call Options (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) was the target of unusually large options trading activity on Monday. Stock investors purchased 832 call options on the stock. This is an increase of 605% compared to the typical volume of 118 call options.
Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $8.50 on Thursday. Corbus Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $10.50. The firm has a market cap of $466.42, a P/E ratio of -13.71 and a beta of 174.68.
Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. The firm had revenue of $0.80 million during the quarter. analysts anticipate that Corbus Pharmaceuticals will post -0.6 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in CRBP. State Board of Administration of Florida Retirement System bought a new stake in Corbus Pharmaceuticals during the third quarter valued at approximately $108,000. Yellowstone Partners LLC bought a new stake in Corbus Pharmaceuticals during the third quarter valued at approximately $110,000. Voya Investment Management LLC bought a new stake in Corbus Pharmaceuticals during the second quarter valued at approximately $125,000. Capital Fund Management S.A. bought a new stake in Corbus Pharmaceuticals during the second quarter valued at approximately $130,000. Finally, Credit Suisse AG bought a new stake in Corbus Pharmaceuticals during the first quarter valued at approximately $157,000. Institutional investors own 27.84% of the company’s stock.
Several research firms have recently weighed in on CRBP. Cantor Fitzgerald set a $28.00 price objective on shares of Corbus Pharmaceuticals and gave the company an “overweight” rating in a report on Thursday, December 14th. BidaskClub cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals in a report on Saturday, December 23rd. Finally, ValuEngine cut shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $25.00.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.